Pricing Log in Create free account
Friday 6 November 2026 Export MRNA’s income statement to Excel — free account

Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue
+2.11%
EPS
+7.51%
Free cash flow
+38.9%
Total debt
+1,765.6%

Quarter to June 2026, against a year earlier

260.02 18.56 +7.69%
Market cap
$96.4B
P/E
0.0×
Fwd P/E
−26.1×
Dividend yield
—
F-score
3/9
Altman Z
2.46
Beneish M
−3.52
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Moderna, Inc. (MRNA) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Moderna, Inc. (MRNA) trades at a EV/Sales of 41.1×. Over the past ten years it has ranged from −2.6× (January 2019) to 521× (May 2020); the current reading is higher than 78% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.2× 16.45%
FY2024 2.8× (45.62%)
FY2023 5.1× 59.76%
FY2022 3.2× (36.02%)
FY2021 5.0× (88.64%)
FY2020 44.0× (51.23%)
FY2019 90.2× —
FY2018 −2.1× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/Sales Change
Jun 2026 10.5× 50.67%
Mar 2026 7.0× 115.05%
Dec 2025 3.2× 28.91%
Sep 2025 2.5× 37.65%
30 more quarters

Against its own ten years

Low −2.6× High 521×
Ten-year median 5.0×
Current reading's percentile 78

EV/Sales against peers

Company EV/Sales
REGN Regeneron Pharmaceuticals, Inc. compare 5.1×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 5.9×
GMAB Genmab A/S Sponsored ADR compare 8.7×
ARGX argenex SE compare 8.9×
VRTX Vertex Pharmaceuticals Incorporated compare 10.4×
RPRX Royalty Pharma PLC compare 14.6×
MRNA Moderna, Inc. 41.1×
RVMD Revolution Medicines, Inc. compare 172×
ROIV Roivant Sciences Ltd. compare 3,061×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on MRNA